This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Anticoagulants Industry

Candidates Against Warfarin II-41

A Comparative Study of Heparin Against Angiomax II-41

A Comparative Study of Arixtra Against UFH and LMWH II-41

A Comparative Study of Angiomax Against UFH and LMWH II-41



Indications for Anticoagulant Use II-42

Venous/DVT Thrombosis Indications II-42

Desired Anticoagulant Qualities for DVT Indications II-42

Venous Thromboembolism II-42

Deep Vein Thrombosis II-42

Pulmonary Embolism II-44

Orthopedic (Hip or Knee Replacement) Surgery II-45

General Surgery II-46

Cancer II-46

Arterial Thrombosis Indications II-47

Arterial Thrombosis II-47

Acute Coronary Syndromes II-47

Atrial Fibrillation II-48

Unstable Angina II-49

List of Approved Anticoagulants for Unstable Angina II-50

Myocardial Infraction II-50

Non ST-Segment Elevation MI II-50

List of Approved Anticoagulants for Non-ST Segment

Elevation Myocardial Infarction II-51

Percutaneous Transluminal Coronary Angioplasty (PTCA) II-51

List of Approved Anticoagulants for Angioplasty Procedures II-52

Heparin Induced Thrombocytopenia (HIT) Indications II-52

HIT Type I II-52

HIT Type II II-52

Heparin Induced Thrombocytopenia with Thrombosis (HITTS) II-54

Other Indications II-54

Hemodialysis II-54



Select Anticoagulants in Clinical Development II-55

Anticoagulant Therapies in Development Stage II-56

Idraparinux - Sanofi II-56

0673 - Sanofi II-56

MER-102 II-56

Semuloparin Sodium (AVE 5026) II-56



Mitsubishi Pharma Introduces Argatroban in the UK II-57

Bayer Obtains Canadian Approval for Xarelto in the Treatment

of Deep Vein Thrombosis II-57

Pradaxa Gains Regulatory Approval in Japan for Prevention of

Stroke II-57

Pfizer and Bristol-Myers Launch ELIQUIS Black Triangle Drug II-57

ELIQUIS® Receives Approval in EU in Prevention of VTE II-58

Xarelto Obtains Approval in UK II-58

Xarelto Receives FDA Approval for Prevention of DVT II-58

Eisai Launches Warfarin Granules 0.2% in Japan II-58

Amphastar Receives FDA Approval for ANDA of Enoxaparin Sodium

Injection II-58

Boehringer Ingelheim Obtains EU Approval for Pradaxa in AF II-59

Daiichi Sankyo Introduces Edoxaban Tablets in Japan II-59


4 of 15

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs